BiotechTube

Fluzoparib+ Dalpiciclib

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma

Conditions

Sarcoma

Trial Timeline

Jul 1, 2023 → Dec 1, 2025

NCT ID
NCT05952128

About Fluzoparib+ Dalpiciclib

Fluzoparib+ Dalpiciclib is a phase 2 stage product being developed by Sun Pharmaceutical for Sarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05952128. Target conditions include Sarcoma.

What happened to similar drugs?

1 of 15 similar drugs in Sarcoma were approved

Approved (1) Terminated (1) Active (13)
🔄Abemaciclib + PlaceboEli LillyPhase 3
🔄cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
🔄Trabectedin + Doxorubicin + IfosfamideJohnson & JohnsonPhase 3
❌LV305 + G305MerckPhase 3
✅Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirMerckApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05952128Phase 2UNKNOWN

Competing Products

20 competing products in Sarcoma

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
19
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
22
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
22
AbemaciclibEli LillyPhase 2
39
Abemaciclib + PlaceboEli LillyPhase 3
44
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
44
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
24
exatecan mesylateDaiichi SankyoPhase 2
35
efatutazoneDaiichi SankyoPhase 2
35
soblidotinDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
LinsitinibAstellas PharmaPhase 2
35
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
42
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
42
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
EribulinEisaiPhase 2
39
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
35
Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + DexamethasoneEisaiPre-clinical
26